* Supernus Pharmaceuticals Inc SUPN.OQ SUPN.O is
expected
to show a rise in quarterly revenue when it reports results on
May 9.
* The Rockville Maryland-based company is expected to
report a
14.9% increase in revenue to $150.471 million from $130.93
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Supernus
Pharmaceuticals
Inc is for earnings of 24 cents per share. For the same quarter
last year, the company reported earnings of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 3.4%
in the last three months.
* Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $35, above its last closing price
of $27.48.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 0.29 0.24 0.04 Missed -83.1
Sep. 30 2021 0.23 0.23 0.40 Beat 72
Jun. 30 2021 0.20 0.20 0.43 Beat 117.7
Mar. 31 2021 0.24 0.24 0.11 Missed -54.6
Dec. 0.59 0.52 0.57 Beat 10.1
31 2020
Sep. 30 2020 0.32 0.30 0.74 Beat 148.7
Jun. 30 2020 0.41 0.42 0.65 Beat 54.8
Mar. 31 2020 0.27 0.28 0.40 Beat 41.8
This summary was machine generated May 6 at 22:16 GMT. All
figures in US dollars unless otherwise stated